Retatrutide Titration Planner

Plan your retatrutide titration schedule week by week. Visualize dose escalation from 2mg to 12mg, see projected drug levels, and estimate weight loss based on Phase 3 TRIUMPH trial data. Free, no signup.

Your Details

lbskg

Time To Goal

Past 24 wks

Proj. Weight 24W

213.8 lbs

Loss % (24W)

14.5%

Max Dose

12mg

Projection Timeline

WeekDateDoseProj. WeightNotes
1Nov 162 mg249.3 lbsInitial tolerance assessment. Common: mild nausea.
2Nov 232 mg248.5 lbs
3Nov 302 mg247.8 lbs
4Dec 72 mg247 lbs
5Dec 144 mg245.8 lbsDose escalation — GI side effects may temporarily increase.
6Dec 214 mg244.5 lbs
7Dec 284 mg243.3 lbs
8Jan 44 mg242.1 lbs
9Jan 118 mg240.4 lbsEntering full therapeutic range. Significant appetite suppression begins.
10Jan 188 mg238.7 lbs
11Jan 258 mg237.1 lbs
12Feb 18 mg235.4 lbs
13Feb 812 mg233.5 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
14Feb 1512 mg231.7 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
15Feb 2212 mg229.8 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
16Mar 112 mg228 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
17Mar 812 mg226.1 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
18Mar 1512 mg224.3 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
19Mar 2212 mg222.5 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
20Mar 2912 mg220.8 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
21Apr 512 mg219 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
22Apr 1212 mg217.2 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
23Apr 1912 mg215.5 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.
24Apr 2612 mg213.8 lbsMaximum dose. ~43% reported nausea at 12mg — usually improves after 4 weeks.

Pharmacokinetic Steady-State & Serum Decay Visualizer (t½ ≈ 144h)

Exponential elimination modeling (k ≈ 0.1155 day⁻¹, τ = 7 days) showing cumulative serum accumulation (R ≈ 1.82) across titration stages 2mg → 4mg → 8mg → 12mg.

t½ = 6d (144h) • R ≈ 1.82
Retatrutide 144-Hour Pharmacokinetic Steady-State Accumulation ModelPharmacokinetic simulation illustrating the ~6-day (144h) elimination half-life and steady-state serum accumulation (accumulation ratio R ≈ 1.82) across the standard 12-week titration protocol (2mg to 12mg).0mg6mg12mg18mg24mgWk1: 2mgWk5: 4mgWk9: 8mgWk13: 12mgWeek 1Week 4Week 8Week 12Week 16
Pharmacokinetic Steady-State Parameters and Receptor Focus by Titration Stage
Titration Stage / Dose (mg)Interval (τ = 7 Days)Cmax Relative (Peak Index)Cmin / Trough (Trough Index)Accumulation Ratio (R)Pharmacodynamic Focus
Phase 1 (Weeks 1–4): 2 mgτ = 7 Days (168h)3.64 mg-eq1.64 mg-eqR ≈ 1.82GLP-1 Gastric Tolerance & Baseline Vagal Adaptation
Phase 2 (Weeks 5–8): 4 mgτ = 7 Days (168h)7.28 mg-eq3.28 mg-eqR ≈ 1.82GIP Insulinotropic Sensitivity & Central Satiety Signaling
Phase 3 (Weeks 9–12): 8 mgτ = 7 Days (168h)14.56 mg-eq6.56 mg-eqR ≈ 1.82Dual Incretin Synergy & Hepatic Lipid Mobilization
Phase 4 (Weeks 13+): 12 mgτ = 7 Days (168h)21.84 mg-eq9.84 mg-eqR ≈ 1.82Glucagon Thermogenesis, Energy Expenditure & Peak Lipolysis
Early-Access Preview • Q4 2026

Metabolic OS & Interactive Titration Companion

Built for Citizen Scientists & Clinicians

Our web titration planner is evolving into a full pharmacokinetic companion app engineered for GLP-1/GIP/glucagon triple-agonist protocols. Upcoming consumer app features include:

Steady-State Half-Life Decay Modeling

Precision simulation of the ~6-day (144h) elimination half-life and cumulative serum concentration peaks.

Lean Mass Retention Tracking

Body composition monitoring (DEXA / BIA) and daily protein targets during rapid adipose tissue loss.

Resting Heart Rate Telemetry

Correlate dose escalations with wearable RHR & HRV trends driven by glucagon receptor agonism.

Smart Injection Reminders

Automated weekly injection site rotation, side-effect logging (dysesthesia, GI), and escalation alerts.

How Retatrutide Titration Works

Retatrutide is a once-weekly injectable triple agonist (GLP-1, GIP, and glucagon receptors) developed by Eli Lilly. The standard titration protocol increases the dose every 4 weeks to minimize gastrointestinal side effects while building toward the therapeutic range.

Standard Titration Schedule

Dosing begins at 2 mg for 4 weeks before increasing to 4 mg, 8 mg, and eventually a 12 mg maintenance dose. This helps the body adapt to the medication gradually.

Why Gradual Titration Matters

Ramping up slowly mitigates severe gastrointestinal side effects like nausea and vomiting. Clinical trial protocols, such as TRIUMPH, carefully scaled the dosage up every four weeks to establish a baseline for tolerability.

TRIUMPH-4 Trial Results

The TRIUMPH-4 and TRIUMPH-1 studies demonstrated that participants taking 12mg of retatrutide experienced an average of 28.7% weight loss at 48 weeks, making it highly effective.

Conservative vs. Standard Titration

For individuals who are highly sensitive to side effects (e.g., severe nausea), a conservative titration profile (1mg → 2mg → 4mg → 8mg → 12mg) may be advised by their healthcare providers. This tool supports custom step calculations.

Frequently Asked Questions

What is the starting dose of retatrutide?

The standard starting dose is 2 mg once weekly, administered subcutaneously.

How long does retatrutide titration take?

The standard protocol reaches the maximum dose of 12 mg in 13 weeks (4 dose levels × 4 weeks each, starting at 2mg).

What side effects should I expect during titration?

The most common side effects are gastrointestinal: nausea (43%), diarrhea (21%), vomiting (21%), and decreased appetite. A unique side effect of retatrutide is dysesthesia (tingling/numbness).

Can I stay on a lower dose if it's working?

Yes. Clinical trials studied 4mg, 8mg, and 12mg as maintenance doses. Many patients achieve satisfactory weight loss at 8mg.

When will retatrutide be available?

Eli Lilly is expected to submit an NDA in late 2026, with a potential PDUFA date in October 2027.

Disclaimer:

This tool is for educational and informational purposes only. It does not constitute medical advice. Retatrutide is an investigational medication not yet approved by the FDA or EMA. Always consult your healthcare provider before starting or modifying any medication. Dosing projections are based on population averages from clinical trials — individual results vary significantly.